Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17089915
PII: file/6163/fb2006a0008.pdf
Knihovny.cz E-resources
- MeSH
- Autoantibodies blood MeSH
- C-Reactive Protein immunology MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy immunology MeSH
- Adult MeSH
- Phagocytosis immunology MeSH
- Interleukin-6 biosynthesis MeSH
- Complement C4 immunology MeSH
- Complement C3 immunology MeSH
- Middle Aged MeSH
- Humans MeSH
- Herpesvirus 1, Human immunology MeSH
- Herpesvirus 2, Human immunology MeSH
- Follow-Up Studies MeSH
- Papillomaviridae immunology MeSH
- Lymphocyte Subsets immunology MeSH
- Antibodies, Viral immunology MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Autoantibodies MeSH
- C-Reactive Protein MeSH
- Interleukin-6 MeSH
- Complement C4 MeSH
- Complement C3 MeSH
- Antibodies, Viral MeSH
In view of the increasing interest in the immunotherapy of CML it seems highly desirable to broaden the present knowledge on the immune reactivity of CML patients. A group of 24 patients and 24 healthy controls were studied for the total of 15 immunological parameters, including the prevalence of antibodies against human herpesviruses and papillomaviruses. To clearly discriminate between changes associated with the disease and those induced by the therapy, all patients were enrolled prior to the start of any anti-leukaemic therapy. Statistically significant differences between patients and controls were found in the levels of IgA, C4 component of complement, CRP and IL-6, the production of Th1 cytokines in stimulated CD3 cells and the E. coli stimulatory index. The analysis of the interrelationship between the results obtained in the individual patients presented some unexpected findings, such as the lack of correlation between the CRP and IL-6 levels. It will be the purpose of a follow-up to determine whether and how the immune status of the patients prior to the treatment correlates with their response to therapy and how the individual immunological profiles change in the course of the disease. These observations will be utilized in the future immunotherapeutic studies to constitute the vaccine- and placebo-treated groups.
Kynurenine and uric acid levels in chronic myeloid leukemia patients
Biological therapy and the immune system in patients with chronic myeloid leukemia